← All trials
NCT04691375
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 29, 2020
- Primary completion
- Oct 28, 2022
- Completion date
- Oct 28, 2022
- First posted
- Dec 31, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 216
- Arms / groups
- 14 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pionyr Immunotherapeutics Inc.Lead sponsor
- Gilead SciencesCollaborator
- Pionyr Immunotherapeutics Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.